Current Issue – 2017 – Volume 20.2

20.2

Clinical Advances and Therapeutic Strategies for Patients with Epilepsy.

 

FDA APPROVED FOR INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS. In COMFORT-I* and COMFORT-II,† Jakafi® (ruxolitinib) significantly reduced spleen volume
compared with patients receiving placebo or best available therapy, respectively 1-3…

READ FULL JOURNAL >>

ARTICLES

20.2-F1-Epilepsy

Clinical Advances and Therapeutic Strategies for Patients with Epilepsy

20.2-F2-IBD

Disease Management Strategies for Moderate to Severe IBD in Adults

20.2-F3-Biosimilars

Exploring Recent Advances in Biosimilars

20.2-F4-Pulmonary

Pulmonary Arterial Hypertension: Toward a Brighter Future for Patients

20.2-F5-OAB

Updated Diagnostic and Individualized Treatment Strategies in the Management of Overactive Bladder

20.2-F6-Prostate

Novel Agents in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

20.2-F7-COPD

Identifying New Strategies to Optimize the Management and Treatment of COPD

20.2-F8-CINV

Chemotherapy-Induced Nausea and Vomiting (CINV): Perceptions, Mechanisms, and Treatment Guidelines

20.2-F9-LDLC

Optimizing Outcomes in Lipid Management: Focusing on LDL-C Reduction